Companies › AFT Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Combogesic® IV Fixed-dose combination of acetaminophen and ibuprofen | PTGS1, PTGS2 | Phase 3 | Acute Pain | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07225634 | Combogesic® IV | Phase 3 | Acute Pain | Other | Mar 2027 |
ZetrOZ Caribou Biosciences Sana Biotechnology Brainfarma Industria Química e Farmacêutica S/A Laboratorios Silanes S.A. de C.V. Sirnaomics
Laboratorios Silanes S.A. de C.V. Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.